On ECHEMI
Home > Drugs > Jiangsu Tasly DIYI Pharmaceutical Co., Ltd.
Jiangsu Tasly DIYI Pharmaceutical Co., Ltd.
  • Founded in:

    1999-03-24
  • Country:

    China China
  • Address:

    No. 168, Chaoyang West Road, Qingpu Industrial Park, Huai'an City
  • Tax NO.:

    91320800139432975C
  • Registered Funds:

    66.86 million yuan
  • Website:

  • Email:

Related Drugs
Inositol Nicotinate Tablets
1,2,3,5/4,6-cyclohexane hexane nicotine ester
Name Description Content CAS NO. Registered Holders
1,2,3,5/4,6-cyclohexane hexane nicotine ester

This product is a mild peripheral vasodilator, which is gradually hydrolyzed into niacin and inositol in the body, so it has the pharmacological effects of both niacin and inositol, and has lipid-lowering effects. Its vasodilating effect is milder and more lasting than that of niacin, and it does not have side effects such as flushing and stomach discomfort after taking niacin. This product can selectively dilate blood vessels in lesions and sensitive areas stimulated by cold, while its dilating effect on normal blood vessels is weaker. In addition, it has the effects of dissolving blood clots, anticoagulation, anti-fatty liver, and reducing capillary fragility.

More

This product is a mild peripheral vasodilator, which is gradually hydrolyzed into niacin and inositol in the body, so it has the pharmacological effects of both niacin and inositol, and has lipid-lowering effects. Its vasodilating effect is milder and more lasting than that of niacin, and it does not have side effects such as flushing and stomach discomfort after taking niacin. This product can selectively dilate blood vessels in lesions and sensitive areas stimulated by cold, while its dilating effect on normal blood vessels is weaker. In addition, it has the effects of dissolving blood clots, anticoagulation, anti-fatty liver, and reducing capillary fragility.

0
Doxycycline Hydrochloride Tablets
The main ingredient of this product is: doxycycline hydrochloride. Its chemical name is: 6-methyl-4-(dimethylamino)-3,5,10,12,12?,-pentahydroxy-1,11-dioxo-1,4,4?,5,5?,6,11,12?-octahydro-2-naphthacenecarboxamide hydrochloride hemiethanol hemihydrate. Molecular formula: C22H24N2O8HCl1/2C2H5OH1/2H2O Molecular weight: 512.93
Name Description Content CAS NO. Registered Holders
Doxycycline hydrochloride

Tetracycline antibiotics are broad-spectrum antibacterial agents with bactericidal effects at high concentrations. They inhibit peptide chain growth and bacterial protein synthesis by binding to the A position of the 30S subunit of the bacterial ribosome. They are effective against a variety of pathogens such as Rickettsia, Mycoplasma, Chlamydia, atypical mycobacteria, and spirochetes. They are more effective against Gram-positive bacteria than Gram-negative bacteria, but enterococci are resistant. Long-term use leads to serious drug resistance, and there is cross-resistance with other tetracycline antibiotics. Animal experiments have confirmed teratogenicity and possible mutagenicity.

More

Tetracycline antibiotics are broad-spectrum antibacterial agents with bactericidal effects at high concentrations. They inhibit peptide chain growth and bacterial protein synthesis by binding to the A position of the 30S subunit of the bacterial ribosome. They are effective against a variety of pathogens such as Rickettsia, Mycoplasma, Chlamydia, atypical mycobacteria, and spirochetes. They are more effective against Gram-positive bacteria than Gram-negative bacteria, but enterococci are resistant. Long-term use leads to serious drug resistance, and there is cross-resistance with other tetracycline antibiotics. Animal experiments have confirmed teratogenicity and possible mutagenicity.

10592-13-9 13
Salicylic acid tablets
The main ingredients of this product and their chemical names: The main ingredient of this product is salicylic acid phenol, and its chemical name is 4-hydroxysalicylic acid anilide.
Name Description Content CAS NO. Registered Holders
2-Hydroxy-N-(4-hydroxyphenyl)-benzamide

Increase liver blood flow, improve liver function, significantly increase the water content in bile, have a stronger choleretic effect than dehydrocholic acid, can relax the sphincter of Oddi, and lower blood cholesterol

More

Increase liver blood flow, improve liver function, significantly increase the water content in bile, have a stronger choleretic effect than dehydrocholic acid, can relax the sphincter of Oddi, and lower blood cholesterol

526-18-1 6
Compound acetaminophen tablets
This product is a compound preparation. Each tablet contains the main ingredients of 126 mg of acetaminophen, 230 mg of aspirin, and 30 mg of caffeine.
Name Description Content CAS NO. Registered Holders
Acetaminophen

By inhibiting cyclooxygenase, it selectively inhibits the synthesis of prostaglandins in the hypothalamic temperature regulation center, leading to peripheral vasodilation and sweating to achieve an antipyretic effect; by inhibiting the synthesis and release of prostaglandins, it increases the pain threshold and has an analgesic effect. It is a peripheral analgesic, weaker than aspirin, and is only effective for mild and moderate pain. This product has no obvious anti-inflammatory effect.

More

By inhibiting cyclooxygenase, it selectively inhibits the synthesis of prostaglandins in the hypothalamic temperature regulation center, leading to peripheral vasodilation and sweating to achieve an antipyretic effect; by inhibiting the synthesis and release of prostaglandins, it increases the pain threshold and has an analgesic effect. It is a peripheral analgesic, weaker than aspirin, and is only effective for mild and moderate pain. This product has no obvious anti-inflammatory effect.

126mg 103-90-2 68
Acetylsalicylic acid

By inhibiting cyclooxygenase, it selectively inhibits the synthesis of prostaglandins in the hypothalamic temperature regulation center, leading to peripheral vasodilation and sweating to achieve an antipyretic effect; by inhibiting the synthesis and release of prostaglandins, it increases the pain threshold and has an analgesic effect. It is a peripheral analgesic, weaker than aspirin, and is only effective for mild and moderate pain. This product has no obvious anti-inflammatory effect.

More

By inhibiting cyclooxygenase, it selectively inhibits the synthesis of prostaglandins in the hypothalamic temperature regulation center, leading to peripheral vasodilation and sweating to achieve an antipyretic effect; by inhibiting the synthesis and release of prostaglandins, it increases the pain threshold and has an analgesic effect. It is a peripheral analgesic, weaker than aspirin, and is only effective for mild and moderate pain. This product has no obvious anti-inflammatory effect.

230mg 50-78-2 35
Caffeine

No specific pharmacological effects mentioned

More

No specific pharmacological effects mentioned

30mg 0
Cilostazol
The main ingredient of this product is cilostazol, and its chemical name is 6-[4-(1-cyclohexyl-1H-tetrazolyl-5-yl)-butoxy]-3,4-dihydro-2(1H)quinolone.
Name Description Content CAS NO. Registered Holders
Cilostazol

It exerts antiplatelet and vasodilator effects by inhibiting the activity of phosphodiesterase in platelets and vascular smooth muscle, increasing the cAMP concentration in platelets and smooth muscle; inhibiting the initial and secondary platelet aggregation and release reactions induced by ADP, adrenaline, collagen and arachidonic acid; not interfering with the synthesis of vascular protective prostacyclin by vascular endothelial cells; for patients with chronic arterial occlusion, it can increase tissue blood flow in the foot and gastrocnemius muscles, increase the lower limb blood pressure index, increase skin blood flow and skin temperature of the limbs, and improve intermittent claudication.

More

It exerts antiplatelet and vasodilator effects by inhibiting the activity of phosphodiesterase in platelets and vascular smooth muscle, increasing the cAMP concentration in platelets and smooth muscle; inhibiting the initial and secondary platelet aggregation and release reactions induced by ADP, adrenaline, collagen and arachidonic acid; not interfering with the synthesis of vascular protective prostacyclin by vascular endothelial cells; for patients with chronic arterial occlusion, it can increase tissue blood flow in the foot and gastrocnemius muscles, increase the lower limb blood pressure index, increase skin blood flow and skin temperature of the limbs, and improve intermittent claudication.

73963-72-1 29
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.